Lipoplexes (LPs) are well-established nucleic acid carriers that utilize cationic lipids to form stable complexes with mRNA through electrostatic interactions. Since their first demonstration in the 1980s, LPs have become a versatile delivery platform, particularly valuable for in vitro and ex vivo applications due to their tunable surface charge, high transfection efficiency, and excellent mRNA protection capability.
Today, LP technology continues to evolve with advanced lipid formulations that improve delivery efficiency while reducing cytotoxicity. At Creative Biolabs, we leverage this mature yet innovative platform to develop customized LP solutions for cell therapy engineering, vaccine research, and other cutting-edge applications requiring precise mRNA delivery.
Lipoplexes (LPs) are a well-established and highly adaptable non-viral mRNA delivery platform, offering tunable physicochemical properties and broad compatibility with diverse therapeutic and research applications. By optimizing cationic lipid composition, charge ratio (N/P), and formulation parameters, LPs can be customized to meet specific delivery challenges in multiple fields. Below, we highlight key application areas where LP delivers exceptional performance.
| Application Area | Key Uses | Technical Advantages |
|---|---|---|
| Cell Therapy & Ex Vivo Engineering | CAR-T/NK cell engineering, Stem cell reprogramming, Primary immune cell transfection |
|
|
||
|
||
| Vaccine Development & Immunotherapy | mRNA vaccines, DC-targeted delivery, Adjuvant co-delivery systems |
|
|
||
|
||
| Gene Editing & Rare Disease Therapy | CRISPR-Cas9 delivery, Protein replacement, In vivo gene correction |
|
|
||
|
||
| In Vivo mRNA Delivery | Liver/lung/tumor targeting, Neurological disease applications |
|
|
||
|
||
| Research & Drug Discovery | mRNA therapeutic screening, Delivery mechanism studies, Stable cell line generation |
|
|
||
|
Each mRNA delivery challenge possesses its own specific characteristics when you face hard-to-transfect cells alongside optimizing immune responses and tissue-specific delivery targets. Our LP platform avoids standardized solutions for all applications. We partner with you to create custom formulations which meet your biological model specifications alongside your therapeutic objectives and scaling needs. Our expertise extends from initial lipid screening all the way through performance validation to optimize your LP system for success.
The shift from research to preclinical development should build upon existing work rather than starting anew. The LP platform includes scalable production workflows and stringent quality control alongside documentation support to rigorous research standards while supporting preclinical development. Our processes help you advance cell therapies, vaccines or gene editing tools by providing confidence in moving your research from the laboratory stage to preclinical studies.
The creation of successful mRNA delivery mechanisms extends beyond particle formulation and involves collaborative knowledge from chemistry, biology, and pharmacology. We deliver complete support throughout all project phases that include design initiation and optimization through both in vitro and in vivo testing. Through our collaborative problem-solving approach and transparent communication, we integrate seamlessly into your team structure enabling you to tackle challenges while speeding up project timelines.
Creative Biolabs's LP Development Workflow delivers turnkey solutions from design to large-scale production for preclinical studies. The diagram shows our streamlined process: starting with consultation & lipid screening, we optimize formulations through iterative testing before advancing to in vitro/in vivo validation and final scale-up. Each phase includes built-in QC checkpoints while allowing flexibility for refinement - ensuring your project stays on track without sacrificing optimization depth.
Fig.1 Systematic Development Workflow for LP Platform Optimization.
Get a Customized Quote
A: LPs are nano-sized complexes formed when cationic lipids electrostatically bind and protect mRNA, enabling efficient cellular delivery through endocytosis and membrane fusion mechanisms.
A: While both are non-viral delivery systems, LPs offer simpler composition control (typically 2-3 lipids vs. 4 in LNPs) and superior charge tunability, making them ideal for ex vivo applications requiring precise transfection.
A: Our LP platform shows exceptional performance in hard-to-transfect cells including T cells, NK cells, stem cells, and primary epithelial cells.
A: We quantify delivery success through flow cytometry (for cellular uptake), qPCR (mRNA quantification), and functional protein expression assays.
A: Yes! Through surface modifications like PEGylation and ligand conjugation (e.g., GalNAc for liver targeting), we can enhance tissue specificity.
A: Every batch undergoes DLS (size/PDI), zeta potential, encapsulation efficiency, endotoxin, and sterility testing.
Creative Biolabs combines cutting-edge lipoplex (LP) technology with decades of mRNA delivery expertise to develop customized non-viral delivery solutions. Our platform delivers optimized LP formulations through precise control of cationic lipid composition, N/P ratios, and surface modifications, ensuring high transfection efficiency across diverse cell types and applications. From initial lipid screening to large-scale production, we provide end-to-end development services supported by rigorous quality control and technical guidance. Whether you're engineering cell therapies, developing vaccines, or advancing gene editing programs, our LP solutions offer the perfect balance of delivery efficiency, payload protection, and preclinical development potential. Contact us to accelerate your mRNA research with tailored LP formulations that meet your exact specifications.
